Vulvovaginal Candidiasis - Market Insight, Epidemiology and Market Forecast - 2027

Vulvovaginal Candidiasis - Market Insight, Epidemiology and Market Forecast - 2027

  • Pages: 120
  • Geography: Global
  • Delivery Timeline: 5 Business Days
  • Publication: Aug, 2018
  • SKU: DIMI0237
  • Single User License
    (20% Off)
    $6,250.00
  • Site License
    (30% Off)
    $12,500.00
  • Global License
    (40% Off)
    $18,750.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight’s ‘Vulvovaginal Candidiasis  - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Vulvovaginal Candidiasis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Vulvovaginal Candidiasis from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan

Study Period: 2016-2027
Vulvovaginal Candidiasis - Disease Understanding and Treatment Algorithm
Vulvovaginal candidiasis (VVC) is an infection caused by Candida species that affects millions of women every year. The development of VVC is usually attributed to the disturbance of the balance between Candida vaginal colonization and host environment by physiological or non-physiological changes.
The DelveInsight Vulvovaginal Candidiasis market report gives the thorough understanding of the Vulvovaginal Candidiasis by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Vulvovaginal Candidiasis in the US, Europe, and Japan.

Vulvovaginal Candidiasis Epidemiology
The Vulvovaginal Candidiasis epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Prevalent Cases, Age Specific Prevalence, and other sub-segmentation type] scenario of Vulvovaginal Candidiasis in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to Centers for Disease Control and Prevention (CDC), Vulvovaginal Candidiasis is the second most common type of vaginal infection after bacterial vaginal infections in the United States. Approximately 75.0% of all women aged 18 to 85 years (mean 32.0 years) in a study of vaginitis in a family practice clinic reported at least episode of VVC in their lives.
 
Vulvovaginal Candidiasis Drug Chapters
This segment of the Vulvovaginal Candidiasis report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
The current availability of over-the-counter (OTC) medications for Vulvovaginal candidiasis (VVC) is a convenient option for many women, although the accuracy of self-diagnosis is questionable. There are variety of effective treatments that include topical or oral antifungals. Currently available options for the treatment of this condition include antifungal intravaginal agents such as butoconazole, clotrimazole, miconazole, and tioconazole, available as OTC. Already approved antifungal agent, Diflucan (Pfizer) is being administered as a single dose oral medication for treatment of uncomplicated yeast infection.

Vulvovaginal Candidiasis Market Outlook
The Vulvovaginal Candidiasis market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 
Emerging therapies such as Candiplus (Profem), MAT2203 (Matinus Biopharma), NDV-3A (NovaDigm Therapeutics), VT-1161 (Viamet Pharmaceuticals) and other compelling treatments, are expected to impact the market size of Vulvovaginal Candidiasis in upcoming years.

Vulvovaginal Candidiasis Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Vulvovaginal Candidiasis Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies

Vulvovaginal Candidiasis Report Key Strengths

• 10 Years Forecast

• 7MM Coverage 

• Epidemiology Segmentation

• Sub-type Segmentation

• Key Cross Competition 

• Highly Analyzed Market

• Drugs Uptake

Vulvovaginal Candidiasis Report Assessment

• Current Treatment Practices

• Unmet Needs

• Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Vulvovaginal Candidiasis market

• Organize sales and marketing efforts by identifying the best opportunities for Vulvovaginal Candidiasis market

• To understand the future market competition in the Vulvovaginal Candidiasis market.

1. Report Introduction
2. Vulvovaginal Candidiasis Market Overview at a Glance
2.1. 7 Major Market Size (%) of Vulvovaginal Candidiasis  in 2017
2.2. 7 Major Market Size (%) of Vulvovaginal Candidiasis  in 2027
3. Disease Background and Overview: Vulvovaginal Candidiasis    
3.1. Introduction
3.2. Causes
3.3. Pathophysiology
3.4. Symptoms
3.5. Risk Factor
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. 7MM Prevalent Cases of Vulvovaginal Candidiasis (2016-2027)
4.2. 7MM Age-Specific Prevalent Cases of Vulvovaginal Candidiasis (2016-2027)
5. Vulvovaginal Candidiasis : Country- Wise Epidemiology
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent Cases of Vulvovaginal Candidiasis (2016-2027)
5.1.3. Age Specific Prevalent Cases of Vulvovaginal Candidiasis (2016-2027)
5.2. EU-5
5.2.1. Assumptions and Rationale
5.2.2. Germany
5.2.2.1. Prevalent Cases of Vulvovaginal Candidiasis (2016-2027)
5.2.2.2. Age Specific Prevalent Cases of Vulvovaginal Candidiasis (2016-2027)
5.2.3. France
5.2.3.1. Prevalent Cases of Vulvovaginal Candidiasis (2016-2027)
5.2.3.2. Age Specific Prevalent Cases of Vulvovaginal Candidiasis (2016-2027)
5.2.4. Italy
5.2.4.1. Prevalent Cases of Vulvovaginal Candidiasis (2016-2027)
5.2.4.2. Age Specific Prevalent Cases of Vulvovaginal Candidiasis (2016-2027)
5.2.5. Spain
5.2.5.1. Prevalent Cases of Vulvovaginal Candidiasis (2016-2027)
5.2.5.2. Age Specific Prevalent Cases of Vulvovaginal Candidiasis (2016-2027)
5.2.6. United Kingdom
5.2.6.1. Prevalent Cases of Vulvovaginal Candidiasis  (2016-2027)
5.2.6.2. Age Specific Prevalent Cases of Vulvovaginal Candidiasis (2016-2027)
5.3. Japan
5.3.1. Assumptions and rationale
5.3.2. Prevalent Cases of Vulvovaginal Candidiasis (2016-2027)
5.3.3. Age Specific Prevalent Cases of Vulvovaginal Candidiasis (2016-2027)
6. Treatments & Medical Practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Marketed Products
7.1. Diflucan: Pfizer
7.1.1. Drug Description
7.1.2. Mechanism of Action
7.1.3. Regulatory Milestones
7.1.4. Advantages and Disadvantages
7.1.5. Safety and Efficacy
7.1.6. Product Profile
List to be continued in report…
8. Emerging Therapies
8.1. Key Cross Competition
8.2. VT-1161 : Viamet Pharmaceuticals
8.2.1. Regulatory Milestones
8.2.2. Clinical Development
8.2.3. Product Profile
8.2.4. Clinical Pipeline Activity
8.2.4.1. Ongoing Trials Information
8.2.4.2. Clinical Trial by Phase
8.3. Candiplus: ProFem
8.3.1.  Regulatory Milestones
8.3.2.  Clinical Development
8.3.3.  Product Profile
8.3.4.  Clinical Pipeline Activity
8.3.4.1. Ongoing Trials Information
8.3.4.2. Clinical Trial by Phase
8.4. MAT2203: Matinus Biopharma
8.4.1. Regulatory Milestones
8.4.2.  Clinical Development
8.4.3.  Product Profile
8.4.4.  Clinical Pipeline Activity
8.4.4.1. Ongoing Trials Information
8.4.4.2. Clinical Trial by Phase
8.5. NDV-3A: NovaDigm Therapeutics
8.5.1. Regulatory Milestones
8.5.2. Clinical Development
8.5.3. Product Profile
8.5.4. Clinical Pipeline Activity
8.5.4.1. Ongoing Trials Information
8.5.4.2. Clinical Trial by Phase
List to be continued in report…
9. Vulvovaginal Candidiasis   Market Size
9.1. Key Findings
9.2. Total 7MM Vulvovaginal Candidiasis Market Analysis 
9.2.1. Overview of Total Vulvovaginal Candidiasis Market 
9.2.2.  Market size of Vulvovaginal Candidiasis Market by 7MM (2016-2027)
10. 7MM: Country-Wise Market Analysis
10.1. United States Market Size
10.1.1. Total Market Size of Vulvovaginal Candidiasis   
10.1.2. Market Size of Vulvovaginal Candidiasis by Therapies
10.2. Germany Market Size
10.2.1. Total Market Size of Vulvovaginal Candidiasis   
10.2.2. Market Size of Vulvovaginal Candidiasis by Therapies
10.3. France Market Size
10.3.1. Total Market Size of Vulvovaginal Candidiasis   
10.3.2. Market Size of Vulvovaginal Candidiasis by Therapies
10.4. United Kingdom Market Size
10.4.1. Total Market Size of Vulvovaginal Candidiasis   
10.4.2. Market Size of Vulvovaginal Candidiasis by Therapies
10.5. Spain Market Size
10.5.1. Total Market Size of Vulvovaginal Candidiasis   
10.5.2. Market Size of Vulvovaginal Candidiasis by Therapies
10.6. Italy Market Size
10.6.1. Total Market Size of Vulvovaginal Candidiasis   
10.6.2. Market Size of Vulvovaginal Candidiasis by Therapies
10.7. Japan Market Size
10.7.1. Total Market Size of Vulvovaginal Candidiasis   
10.7.2. Market Size of Vulvovaginal Candidiasis by Therapies
11. Market Drivers
12. Market Barriers
13. Report Methodology
13.1. Sources Used
14. DelveInsight Capabilities
15. Disclaimer
16. About DelveInsight

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Table 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Table 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Table 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Table 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Table 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Table 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Table 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Table 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Table 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Table 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Table 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Table 17 VT-1161, Clinical Trials by Recruitment status, 2018
Table 18 VT-1161, Clinical Trials by Zone, 2018
Table 19 Candiplus, Clinical Trials by Recruitment status, 2018
Table 20 Candiplus, Clinical Trials by Zone, 2018
Table 21 MAT2203, Clinical Trials by Recruitment status, 2018
Table 22 MAT2203, Clinical Trials by Zone, 2018
Table 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Table 24 NDV-3A, Clinical Trials by Zone, 2018
Table 25 Total 7 Major Market Size in USD, Million (2016-2027)
Table 26 Region wise Market Size) in USD, Million (2016-2027)
Table 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Table 28 United States Market Size in USD, Million (2016-2027)
Table 29 United States Market Size by Therapy in USD, Million (2016-2027)
Table 30 Germany  Market Size in USD, Million (2016-2027)
Table 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Table 32 France  Market Size in USD, Million (2016-2027)
Table 33 France Market Size by Therapy in USD, Million (2016-2027)
Table 34 United Kingdom  Market Size in USD, Million (2016-2027)
Table 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Table 36 Spain Market Size in USD, Million (2016-2027)
Table 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Table 38 Italy Market Size in USD, Million (2016-2027)
Table 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Table 40 Japan Market Size in USD, Million (2016-2027)
Table 41 Japan Market Size by Therapy in USD, Million (2016-2027)

 

Figure 1 Prevalent Cases of Vulvovaginal Candidiasis in 7MM (2016-2027)
Figure 2 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in 7MM (2016-2027)
Figure 3 Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 4 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the US (2016-2027)
Figure 5 Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 6 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Germany (2016-2027)
Figure 7 Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 8 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in Italy (2016-2027)
Figure 9 Prevalent Cases of Vulvovaginal Candidiasis  in Spain (2016-2027)
Figure 10 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Spain (2016-2027)
Figure 11 Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 12 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in France (2016-2027)
Figure 13 Prevalent Cases of Vulvovaginal Candidiasis in the UK (2016-2027)
Figure 14 Age Specific Prevalent Cases of Vulvovaginal Candidiasis  in the UK (2016-2027)
Figure 15 Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 16 Age Specific Prevalent Cases of Vulvovaginal Candidiasis in Japan (2016-2027)
Figure 17 VT-1161, Clinical Trials by Recruitment status, 2018
Figure 18 VT-1161, Clinical Trials by Zone, 2018
Figure 19 Candiplus, Clinical Trials by Recruitment status, 2018
Figure 20 Candiplus, Clinical Trials by Zone, 2018
Figure 21 MAT2203, Clinical Trials by Recruitment status, 2018
Figure 22 MAT2203, Clinical Trials by Zone, 2018
Figure 23 NDV-3A, Clinical Trials by Recruitment status, 2018
Figure 24 NDV-3A, Clinical Trials by Zone, 2018
Figure 25 Total 7 Major Market Size in USD, Million (2016-2027)
Figure 26 Region wise Market Size) in USD, Million (2016-2027)
Figure 27 7MM-Market Size by Therapy in USD, Million (2016-2027)
Figure 28 United States Market Size in USD, Million (2016-2027)
Figure 29 United States Market Size by Therapy in USD, Million (2016-2027)
Figure 30 Germany  Market Size in USD, Million (2016-2027)
Figure 31 Germany Market Size by Therapy in USD, Million (2016-2027)
Figure 32 France  Market Size in USD, Million (2016-2027)
Figure 33 France Market Size by Therapy in USD, Million (2016-2027)
Figure 34 United Kingdom  Market Size in USD, Million (2016-2027)
Figure 35 United Kingdom Market Size by Therapy in USD, Million (2016-2027)
Figure 36 Spain Market Size in USD, Million (2016-2027)
Figure 37 Spain Market Size by Therapy in USD, Million (2016-2027)
Figure 38 Italy Market Size in USD, Million (2016-2027)
Figure 39 Italy Market Size by Therapy in USD, Million (2016-2027)
Figure 40 Japan Market Size in USD, Million (2016-2027)
Figure 41 Japan Market Size by Therapy in USD, Million (2016-2027)
Figure 42 Market Drivers
Figure 43 Market Barriers

 

Key Companies
Speak to Analyst
Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Specific Filed of Interest*  
X

Speak to Analyst

+1(919)321-6187

Related Reports

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Copyright © 2018 Delveinsight.